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Background: In this study we compared the outcomes of the everolimus-eluting stent (EES) 
versus the zotarolimus-eluting stent (ZES) in patients treated at a tertiary medical center, with 
up to one year of follow-up.
Methods: Unselected consecutive patients were retrospectively recruited following stenting 
with the ZES (n = 197) or EES (n = 190). The first 100 consecutive patients in each cohort 
underwent syntax scoring. The primary endpoint of the study was target vessel failure, defined 
as the combined endpoint of cardiac death, non-fatal myocardial infarction, or target ves-
sel revascularization. Secondary endpoints included target lesion revascularization, target 
lesion failure, acute stent thrombosis, total death, cardiac death, and non-fatal myocardial 
infarction.
Results: The two groups were similar, including for Syntax scores (19.6 ± 12.8 versus 
20.6 ± 13.6), number of stents per patient (2.9 ± 1.9 versus 2.9 ± 2.1), and cardiovascular risk 
factors. By one year, the primary outcome occurred in 20.8% EES versus 26.7% ZES (P = 0.19) 
patients. The secondary endpoints were as follows: target lesion revascularization (8.9% versus 
20.6%, P = 0.003), target vessel revascularization (18.9% versus 25.6%, P = 0.142), definite and 
probable stent thrombosis (0% versus 2.5%), non-fatal myocardial infarction (2.7% versus 3.6%), 
and mortality (3.2% versus 5.1%) for the EES versus the ZES, respectively.
Conclusion: EES had similar target vessel failure to ZES, but superior target lesion revascular-
ization and target lesion failure at one year of follow-up in an unselected cohort of patients.
Keywords: coronary stent, drug eluting stent, zotarolimus, everolimus, outcome, target lesion 
revascularization, stent thrombosis
Introduction
The zotarolimus-eluting stent (ZES), Endeavor® (Medtronic, Minneapolis, MN) 
and the everolimus-eluting stent (EES), Xience® or Promus™ (Abbott Laboratories, 
Abbott Park, IL) are second-generation drug-eluting stents with lower target lesion 
revascularization and adverse event rates than bare metal stents.1–4
The ZES and EES stents have been compared in randomized trials with the 
paclitaxel-eluting stent (Boston Scientific, San Diego, CA) and the sirolimus-eluting 
stent (Cordis Corporation, Bridgewater, NJ),5–7 but few comparative data exist 
between the Endeavor ZES and the EES. Herrador et al8 compared the ZES and EES 
in coronary bifurcating lesions, and found higher 12-month adverse event and target 
lesion revascularization rates in the ZES group. Recently, a new ZES, the Resolute™ 
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(Medtronic, Minneapolis, MN) was compared with the EES 
in a large randomized trial, with no differences in outcomes 
found between these two stents.9 However, the Resolute 
ZES had prolonged elution of the drug compared with the 
Endeavor ZES. Compared with historic controls, the Reso-
lute ZES stent outperformed the Endeavor ZES stent, with 
superior target lesion and vessel revascularization.10 In this 
single-center study, we compared the Endeavor ZES and the 
EES for late outcomes at one year in an unselected consecu-
tive group of patients.
Materials and methods
Unselected consecutive patients were retrospectively 
recruited from a single center following stenting with the 
ZES or the EES. Both de novo and restenotic lesions were 
included. Patients with bypass graft stenting or who received 
mixed stents were excluded. The first 100 consecutive patients 
in each cohort underwent Syntax scoring by an independent 
investigator blinded to patients’ outcomes. The investiga-
tor underwent basic training in Syntax scoring using the 
online tutorial on the Syntax score website (http://www.
syntaxscore.com) followed by extensive training with an 
interventional cardiologist experienced in Syntax scoring and 
having performed over 50 cases with close supervision.
Tables 1 and 2 show the demographic, clinical, and pro-
cedural variables collected by reviewing medical records. 
Angiographic variables are shown in Table 2, and were 
obtained by independent reviewing of the angiograms 
by an investigator blinded to patient outcomes. Ejection 
fraction was obtained from the procedural records as 
assessed qualitatively during the index procedure using left 
ventriculography.
Follow-up was limited to one year from the index proce-
dure and was performed using medical records, phone calls, or 
both. Patients were initially mailed a brief letter describing the 
protocol, followed by a phone call to obtain verbal consent to 
be part of the study (using a standardized script approved by 
our institutional review board). All events reported by patients 
were verified by cross-reference to medical records. Patients 
who were deceased had their death certificate retrieved when 
possible to evaluate the cause of death.
The primary outcome of the study was target vessel 
failure (defined as cardiac death, non-fatal myocardial 
infarction, and target vessel revascularization). Secondary 
outcomes included target lesion revascularization, target 
vessel revascularization, target lesion failure (defined as 
cardiac death, non-fatal myocardial infarction, and target 
lesion revascularization), acute stent thrombosis as defined by 
the Academic Research Consortium,11 non-fatal myocardial 
infarction, and cardiac death.
Statistical analysis
Descriptive analysis was performed on all variables. The 
t-test was used for continuous variables and Chi-square 
testing for dichotomous variables. Univariate analysis 
compared the demographic, clinical, angiographic, and 
Table 1 Demographic and clinical variables
n Zotarolimus n Everolimus P value
Age (years) 197 66.9 ± 12.2 189 65.7 ± 11.4 0.300
Body mass index 197 30.5 ± 6.9 187 30.9 ± 6.6 0.587
Male (%) 133/197 67.5 126/190 66.3 0.829
New York Heart Association class (%) 197 189 0.208
No symptoms/Class I 155 78.7 158 83.6
Class II 23 11.7 26 13.8
Class III 7 3.6 3 1.6
Class IV 12 6.1 2 1.1
Prior percutaneous coronary intervention (%) 133/197 67.5 142/189 75.1 0.115
Prior coronary artery bypass surgery (%) 43/197 21.8 47/190 24.7 0.548
Previous myocardial infarction (%) 57/197 28.9 74/190 38.9 0.041
Family history of premature coronary disease (%) 97/197 49.2 75/186 40.3 0.082
Renal failure (%) 11/197 5.6 8/186 4.3 0.642
Peripheral vascular disease (%) 30/197 15.2 21/190 11.1 0.233
History of hypertension (%) 151/197 76.6 153/190 80.5 0.387
Cerebrovascular disease (%) 32/197 16.2 2/190 4.7 0.001
Hyperlipidemia (%) 166/197 84.3 161/190 84.7 1.000
History of smoking (current and ex-smoker, %) 129/197 65.5 121/189 64 0.831
Diabetes mellitus (%) 72/197 36.5 70/189 37 1.000
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outcome variables between the two groups. Survival analysis 
(Kaplan-Meier) was performed for target vessel failure over 
one year of follow-up. SPSS (IBM, New York, NY) software 
was used to conduct the analysis.
Results
A total of 235 ZES and 208 EES patients met the inclusion 
criteria and were recruited to the study. Patients were 
excluded if they refused to give the verbal consent required 
by the institutional review board (n = 25 ZES, n = 10 EES) 
or were lost to follow-up (n = 13 ZES, n = 8 EES). A total 
of 197 ZES patients (270 vessels, 403 segments) and 190 
EES patients (306 vessels, 479 segments) were included in 
the final analysis.
Descriptive analysis for all patients is shown in Table 1. 
There was a high proportion of patients who had had prior 
percutaneous coronary intervention and prior bypass surgery 
in both cohorts. Approximately two thirds of the patients 
were current or prior smokers and 36.5% were diabetics. 
There were no statistical differences for any of the clinical 
and demographic variables between the EES and ZES stents, 
except for a higher incidence of prior myocardial infarction 
in the EES group (38.9% versus 28.9%; P = 0.041) and a 
higher incidence of cerebrovascular disease in the ZES group 
(16.2% versus 4.7%; P = 0.001). Also, there was no bias 
regarding utilization of particular stent types at the medical 
center between the 11 interventionalists, who used the ZES 
and EES at the same statistical frequency.
Indications for the procedure were similar between the 
two groups, with about half the patients treated for an acute 
coronary syndrome. The distribution of disease was also 
similar between the cohorts, with 6%–10% of patients hav-
ing had their left main stem treated (Table 2). Angiographic 
and   procedural variables are shown in Table 3. There 
was a relatively high number of stents placed per patient 
(2.8–2.9 stents), and approximately one third of patients had 
restenotic index lesions. Patients in the EES group had a lower 
ejection fraction than those in the ZES group (51.5% versus 
59.7%, P = 0.001); however, ejection fractions were in the 
normal range in both groups. Long lesion lengths were noted, 
but were similar in both groups. The Syntax scores for the 
first 100 consecutive patients, which reflect angiographic 
complexity, were statistically nearly identical between the 
EES and ZES (19.6 ± 12.8 versus 20.6 ± 13.6).
At one-year follow-up, target vessel failure was 26.7% 
for the ZES versus 20.8% for the EES (P = 0.19, Figure 1, 
Table 4). The secondary endpoint of target lesion revascu-
larization (20.6% versus 8.9%, P = 0.003) was superior for 
the ZES versus the EES. Target vessel revascularization 
(26.7% versus 20.8%), cardiac death (2.0% versus 1.6%), 
non-cardiac death (2.1% versus 1.1%), and definite and prob-
able stent thrombosis (2.5% versus 0%) trended in favor of 
the EES, but no statistical difference was seen.
Clinical history of patients with definite 
or probable acute stent thrombosis
Five patients in the ZES cohort had definite or probable stent 
thrombosis. The first patient was a 92-year-old female with 
a prior myocardial infarction and a history of hypertension. 
Stent thrombosis occurred 7 days after the index procedure. 
She was on clopidogrel and aspirin. She underwent target 
lesion revascularization but later died during the same 
Table 2 Indications for angiography and coronary artery distribution
Zotarolimus Everolimus P value
Indications for  
angiography (%)
0.979
Unstable angina/NSTEMI 43.5 49.8
STEMI 4.8 2.4
Abnormal perfusion  
test with symptoms
17.7 15.3
Abnormal perfusion  
test with no symptoms
6.7 6.2
Cardiomyopathy/ 
congestive heart failure
1.4 0.5
Staged intervention 23.4 23.9
Arrhythmias 1.4 0.9
Recent decrease  
in ejection fraction
0 1
Progressive dyspnea 1 0
Number of patients  
treated (n)
197 190
Number of vessels  
treated (n)*
270 306
Number of segments  
treated (n)**
403 479
Distribution of coronary  
artery disease (per number  
of vessels, %)
0.835
Right coronary artery 24.8 20.9
Left main stem 6.3 9.8
Left anterior  
descending artery
35.4 35.9
Ramus intermedius 4.4 4.6
Left circumflex 29.1 28.8  
Notes: *The following were considered vessels per patient and counted when 
treated: LAD, LCX, RI, RCA, and LM; **The following segments were considered 
per  vessel  and  counted  when  treated:  LAD,  proximal,  mid,  distal,  diagonal 
1 and 2; LCX, proximal, distal, obtuse marginal 1 and 2, and posterolateral branch 
1 and 2 RCA, proximal, mid, distal, acute marginal, posterior descending artery, 
posterolateral 1 and 2. Disease in LM and RI was considered as one segment per 
vessel.
Abbreviations:  STEMI,  ST  elevation  myocardial  infarction;  NSTEMI,  non-ST 
elevation myocardial infarction; RI, ramus intermedius; LCX, left circumflex; LM, left 
main stem; LAD, left anterior descending; RCA, right coronary artery.
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hospital stay. The second patient was a 49-year-old male 
with a prior myocardial infarction, and hyperlipidemia. 
Stent thrombosis occurred 8 days following the index pro-
cedure. He was on clopidogrel and aspirin. He underwent 
target lesion   revascularization successfully. The third patient 
was a 71-year-old male with history of hyperlipidemia, 
  diabetes mellitus, and prior myocardial infarction. Stent 
thrombosis occurred 100 days following the index procedure. 
He was on aspirin and clopidogrel. He underwent target lesion 
revascularization but later died during the same hospital stay. 
The fourth patient was a 68-year-old male with a history of 
hyperlipidemia, prior tobacco use, and diabetes. He was on 
clopidogrel and aspirin. Stent thrombosis occurred 78 days 
after the index procedure. He underwent successful target 
lesion revascularization. The fifth patient was a 65-year-old 
female with hypertension, hyperlipidemia, diabetes mellitus, 
and a prior history of smoking. Stent thrombosis occurred at 
192 days after the index procedure. She was on clopidogrel 
and aspirin. She underwent target lesion revascularization 
successfully.
Discussion
In this study, the primary outcome occurred in 20.8% of the 
EES versus 26.7% of the ZES (P = 0.19) patients, with no 
differences in the secondary outcome of target vessel revas-
cularization (18.9% versus 25.6%, P = 0.142). However, 
the EES showed superior target lesion revascularization 
(8.9% versus 20.6%, P = 0.003) and target lesion failure 
(11.7 versus 22.6%, P = 0.003) when compared with the 
ZES. Both the ZES and EES have been shown to have lower 
target lesion revascularization and adverse event rates than 
bare metal stents.1–4 However, not all drug-eluting stents 
have similar outcomes. In this study, the EES had a supe-
rior one-year outcome than the ZES, with less target lesion 
revascularization and target lesion failure at the one-year 
follow-up. However, interestingly, target vessel revascular-
ization was the same in both cohorts, resulting in statisti-
cally similar target vessel failure. In this retrospective study, 
there were no predefined endpoints as to when target lesion 
  revascularization could be performed. It is possible that this 
biased the data in favor of the EES, considering that the ZES 
is known to have higher late lumen loss than the EES.12
Table 3 Angiographic and procedural variables
Zotarolimus Everolimus P value
Per patient analysis n = 197 n = 190
Ejection fraction (%) 59.7 ± 13.2 (n = 101) 51.5 ± 143 (n = 152) 0.001
Stents used per patient (n) 2.8 ± 1.8 2.9 ± 2.1 0.690
Length of disease treated per patient (mm) 54 ± 37.4 52.2 ± 43 0.698
Patients treated with restenotic lesions (%) 33.3 42.6 0.104
Percentage of patients with non-left main bifurcating disease (%) 45.6 50.8 0.422
Syntax (first 100 consecutive patient in each group) 19.6 ± 12.8 20.6 ± 13.6 0.592
Per vessel analysis n = 270 n = 306
Stents used per vessel (n) 1.8 ± 1.2 1.8 ± 1.2 0.880
Length of disease treated per vessel (mm) 34.5 ± 25.2 32.4 ± 26.4 0.371
Per segment analysis n = 403 n = 479
Pre lesion severity (%) 71.7 ± 25.1 84.5 ± 11.9 0.001
Post lesion severity (%) 0.2 ± 2 0 0.103
Diameter (mm) 2.8 ± 0.4 3 ± 0.5 0.001
Stents used per segment (n) 1.1 ± 0.5 1.2 ± 0.4 0.029
Length of disease treated per segment (mm) 20.9 ± 9.5 20.7 ± 12.6 0.777
Segments treated with restenotic lesions (%) 28.7 33.9 0.128
Ostial segments treated (%) 8.3 8.2 1.000
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Figure 1 Kaplan-Meier curve showing target vessel failure survival for the Endeavor 
zotarolimus stent (solid line) versus the Everolimus stent (dashed line).
Abbreviation: TVF, target vessel failure.
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The ZES has been compared with the sirolimus-eluting 
stent in randomized trials.5 Insegment binary angiographic 
restenosis was higher in the ZES cohort (11.7% versus 4.3%, 
P = 0.04). At 9 months, total (clinically and non-clinically 
driven) target lesion revascularization rates were 9.8% and 
3.5% for the ZES and sirolimus-eluting stent groups, respec-
tively (P = 0.04). However, clinically driven target lesion 
revascularization and target vessel failure did not differ 
significantly between the two stents. Further, the Endeavour 
ZES has been compared with the paclitaxel-eluting stent in 
the randomized ENDEAVOR IV trial. This trial showed that 
the ZES was noninferior to the paclitaxel-eluting stent at the 
12-month follow-up, with rates of target vessel failure being 
6.6% versus 7.1%, respectively (P # 0.001). In Endeavor IV , 
there were no significant differences between the ZES 
and the paclitaxel-eluting stent for rates of cardiac death, 
myocardial infarction, target vessel revascularization, or 
stent thrombosis.13 At 3-year follow-up, compared with the 
paclitaxel-eluting stent, the ZES showed reduced target ves-
sel failure (12.3% versus 15.9%, P = 0.049) and myocardial 
infarction rates (2.1% versus 4.9%, P = 0.005), with similar 
ischemia-driven target lesion revascularization (6.5% versus 
6.1%, P = 0.662).14
The EES was also compared with the paclitaxel-eluting 
stent in the SPIRIT III trial. At the 2-year follow-up, 
compared with the paclitaxel-eluting stent, patients treated 
with the EES had a significant 32% reduction in target vessel 
failure (10.7% versus 15.4%, P = 0.04) and a 45% reduction 
in major adverse cardiac events (cardiac death, myocardial 
infarction, or target lesion revascularization; 7.3% versus 
12.8%, P = 0.004).7 In the elderly cohort (those .65 years 
of age) of SPIRIT III, the EES-treated patients had lower 
rates of binary insegment restenosis (3.4% versus 15.5%, 
P = 0.004) at 8 months, and a 48% lower incidence of 3-year 
target vessel failure (10.8% versus 20.8%, P = 0.009).15
However, limited comparative data exist for the Endeavor 
ZES and the EES. Herrador et al8 compared the ZES with 
the EES in coronary bifurcating lesions, and found a higher 
12-month adverse events rate (23.1% versus 4.5%, P , 0.001) 
and higher target lesion revascularization (17.5% versus 
3.2%, P , 0.001) in the ZES group. Our study included 
consecutive patients who received EES and ZES from the 
same medical center. EES outperformed the Endeavor ZES at 
the one-year follow-up, with less target lesion failure, driven 
mostly by less target lesion revascularization. However, target 
vessel failure was similar between the two stents at one year. 
Recently the new Resolute ZES (Medtronic) was compared 
with the EES in a large randomized trial and no differences 
in outcome were found between these two stents.9 However, 
the Resolute ZES showed prolonged elution of the drug 
Table 4 Patient outcomes
Zotarolimus Everolimus P value
Duration of follow-up (days) 350.9 ± 55.8 344.6 ± 70.5 0.001
TLR per segment (%) 14.4 6.1 0.001
TLR per vessel (%) 17 7.9 0.002
TLR per patient (%) 20.6 8.9 0.003
TLR per segment (%) 16.7 9.5 0.002
TLR per vessel (%) 20.8 14.5 0.059
TLR per patient (%) 25.6 18.9 0.142
Target lesion failure (%) 22.6 11.7 0.003
Target vessel failure (%) 26.7 20.8 0.19
Stent thrombosis (%) NA
Definite or probable 2.5 0
Possible 0.5 0.5
Patient on clopidogrel at definite or probable stent thrombosis event (%) 100 0 NA
Patient compliance when definite or probably stent thrombosis occurred (%) 100 0 NA
Percent of patients on clopidogrel on follow-up (%) 95.9 93.1 0.256
Percent of patients on aspirin on follow-up (%) 94.3 97.7 0.118
Death classification on follow-up (%)
No 94.9 96.8 NA
Non-cardiac 2.1 1.1
Unknown 1 0.5
Cardiac sudden death probable 1 0
Cardiac non-stent thrombosis 1 1.6
Acute non-ST elevation myocardial infarction, non-fatal (%) 3.6 1.1 0.176
Acute ST elevation myocardial infarction, non-fatal (%) 0 1.6 0.118
Abbreviations: NA, not applicable; TLR, Target lesion revascularization.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
209
Everolimus versus zotarolimus stentsVascular Health and Risk Management 2012:8
compared with the Endeavor ZES. Furthermore, compared 
with historic controls, the Resolute ZES stent outperformed 
the Endeavor stent in data presented recently at the American 
College of Cardiology scientific sessions.10 The longer drug 
elution time of zotarolimus seems to be a key factor in reduc-
ing target lesion revascularization and target vessel failure 
in patients treated with ZES stents. The Resolute ZES stent 
has recently entered the US market and is likely to replace 
the Endeavor ZES.
Overall, the rates of target lesion revascularization and 
target vessel failure with the ZES in our study are higher 
than that in the data published for the Endeavor ZES from 
the real-world prospective, multicenter E-Five registry.1 
The one-year outcome of the Endeavor ZES in the E-Five 
registry showed a target lesion revascularization rate of 4.5% 
and definite/probable stent thrombosis of 0.6%. Our data 
showed a higher target lesion revascularization and stent 
thrombosis rate than the E-Five registry, likely secondary to 
the more complex patients treated at our center. Compared 
with E-Five, our study had more bifurcating lesions (45.6% 
versus 18.9%), ostial lesions (8.3% versus 5.8%), instent 
restenosis (33.3% versus 4.8%), left main stenting (6.3% 
versus 2.4%), and longer total lesion length (54 ± 37.4 ver-
sus 18.51 ± 10.61). Furthermore, there were higher clinical 
risk features in our patients, with more prior percutaneous 
coronary interventions (67.5% versus 25.3%) and bypass sur-
geries (21.8% versus 7.5%). As disease complexity increases 
and major adverse event rates increase, it is more likely that 
small differences between drug-eluting stents would become 
more obvious and significant.
Study limitations
This study is limited by its retrospective nature. However, 
angiographic complexity was assessed using Syntax scoring 
by an investigator blinded to patient outcomes and showed 
no differences between the two cohorts. Interobserver and 
intraobserver variability was not determined in this study. 
However, we utilized a reliable training method recently 
shown to yield at least moderate agreement in Syntax 
calculation.16 We also limited Syntax scoring to the first 
consecutive 100 patients in each cohort. However, the near 
identical results and similar angiographic variables between 
the two cohorts predict a low likelihood that differences will 
emerge in calculating syntax scores for the entire cohort.
It is unlikely that randomized trials will compare the 
Endeavor ZES with the EES because of the recent introduc-
tion of the Resolute ZES to the United States, which has 
proven superior results to the Endeavor ZES. However, these 
data continue to be of significance for patients who have 
already received the ZES and continue to receive the EES.
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